The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future

The NETTER-1 study has proven peptide receptor radionuclide therapy (PRRT) to be one of the most effective therapeutic options for metastatic neuroendocrine tumors (NETs), improving progression-free survival and overall survival. However, PRRT response assessment is challenging and no consensus on m...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Virginia Liberini, Martin W. Huellner, Serena Grimaldi, Monica Finessi, Philippe Thuillier, Alfredo Muni, Riccardo E. Pellerito, Mauro G. Papotti, Alessandro Piovesan, Emanuela Arvat, Désirée Deandreis
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	MDPI AG 2020-12-01
Cyfres:	Diagnostics
Pynciau:	peptide receptor radionuclide therapy PRRT <sup>68</sup>Ga-labeled somatostatin analogue <sup>18</sup>F-FDG response assessment RECIST
Mynediad Ar-lein:	https://www.mdpi.com/2075-4418/10/12/1083
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!